

Date of preparation: 2022-07-06

Abbreviated name of the Issuer: MABION S.A.

Subject matter: Extension of cooperation with Novavax, Inc.

Legal basis: Article 17(1) of MAR - confidential information.

Content of the Report:

With reference to Current Report no. 52/2021 of 8 October 2021 on entering into a commercial contract manufacturing agreement ("Manufacturing Agreement") with Novavax, Inc. ("Novavax") and subsequent current reports regarding the extension of cooperation with Novavax, the Management Board of Mabion S.A. ("Company") hereby informs that on 6 July 2022, it concluded with Novavax a further extension of the services under the Manufacturing Agreement in the form of Statement of Work #6 ("SOW#6").

The scope of SOW#6 is to conduct stability studies on the chromatographic stationary phases used in the production process of the Nuvaxovid vaccine active substance. The studies will be carried out in the production area, in an environment compliant with GMP (Good Manufacturing Practice).

The implementation of work covered by SOW#6 will commence as soon as the order is signed.

In the Management Board's view, the signing of SOW#6 is important for the Company, first and foremost due to the further expansion of the cooperation with Novavax.